No abstract

No abstract

Rationale, aims, and objectives: Current meta-analysis was conducted aiming to assess the efficacy and safety of recombinant human in the treatment of acute leukaemia (AL) patients with chemotherapy-induced thrombocytopenia (CIT). Methods:We searched PubMed, Embase, Chinese National Knowledge Infrastructure database (CNKI), Cochrane Library, and Wan Fang Database on 4 July 2018.Results: Ten randomized controlled trials (RCTs) and two observational studies were included, which involved 754 AL patients with CIT. Pooled analysis demonstrated that rhIL-11 was beneficial on CIT: recovery time of platelet count to 50 × 10 9 /L [weight mean difference (WMD) = −4.19 days; 95% CI: −5.01, −3.37], recovery time of platelet count to 100 × 10 9 /L (WMD = −4.45 days; 95% CI: −4.85, −4.06), platelet transfusion volume (WMD = −6.14 U; 95% CI: −9.20, −3.09), and the rate of haemorrhage (RR = 0.46; 95% CI: 0.36 to 0.61). Most adverse events associated with rhIL-11 were mild to moderate.Conclusion: Our findings suggest that rhIL-11 is effective and safe in the treatment of CIT in patients with AL. KEYWORDS acute leukaemia, chemotherapy-induced thrombocytopenia, meta-analysis, recombinant human interleukin-11 † ZhiRong Liu, Yaxuan Wang, and Jingxin Yan are co-first authors.

No abstract

Rupture of HCC (rHCC) is a life-threatening complication of hepatocellular carcinoma (HCC), and rHCC may lead to a high rate of peritoneal dissemination and affect survival negatively. Treatment for rHCC mainly includes emergency surgery, interventional therapies, and palliative treatment. However, the management of rHCC should be carefully evaluated. For patients with severe bleeding, who are not tolerant to open surgery, quick hemostatic methods such as rupture tissue ablation and TAE/TACE can be performed. We described clinical presentation, prognosis, complication, interventional management, and current evidence of rHCC from the perspective of interventional radiologists. Overall, our review summarized that interventional therapies are necessary for most patients with rHCC to achieve hemostasis, even in some patients with Child–Pugh C. Moreover, TAE/TACE followed by staged hepatectomy is a beneficial treatment for rHCC according to current clinical evidence. TAE/TACE is the first choice for most patients with rHCC, and appropriate interventional treatment may provide staged surgery opportunities for those who are not tolerant to emergency surgery to reach an ideal prognosis.

Background: Bladder cancer (BC) is the 10th most common malignancy worldwide, and some studies reported that ABO blood type or/and rhesus factor has been identified as a prognostic oncologic marker for patients with BC. We carried out a systematic review to assess the prognosis of ABO blood group and rhesus factor on outcomes in patients with bladder cancer. Methods: We searched databases through February 2022 for studies assessing blood group on outcomes in patients with bladder cancer. Results: We included ten studies with 15,204 participants. We found that blood type A is relevant to non-muscle-invasive BC patients treated with transurethral resection of bladder tumor and blood type B patients have a lower incidence of disease recurrence and progression. Blood type O and non-O blood type have not been found to be related to disease recurrence. However, in multivariable analyses, blood type O and non-O blood type are associated with cancer-specific mortality (CSM). Other than that, blood type B doesn’t have statistical significance for BC patients accepted radical cystectomy (RC). The same results showed in blood type AB non-muscle-invasive bladder cancer patients treated with RC. Conclusions: Our study confirmed that a particular association of blood type for prognosis of patients with BC, and ABO blood group antigen expression can be suitable biomarkers for BC. We also found that rhesus factor has no impact on prognosis of BC patients.

No abstract

No abstract